Ex vivo gene transfer for improved adoptive immunotherapy of cancer

Human Molecular Genetics

Volumn 20, Issue , 2011, Pages

  Ngo, Minhtran C ^a   Rooney, Cliona M ^a   Howard, Jeffrey M ^a   Heslop, Helen E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; OKT 3;

ARTICLE; CANCER IMMUNOTHERAPY; CELL TRANSFER; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DNA MODIFICATION; EX VIVO GENE TRANSFER; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LYMPHOMA; MELANOMA; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PATIENT SAFETY; PRIORITY JOURNAL; SUICIDE GENE; T LYMPHOCYTE; TRANSGENICS;

ANIMALS; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 79956028898     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr102     Document Type: Article

References (61)

1. Perez-Gracia, J.L., Berraondo, P., Martinez-Forero, I., Alfaro, C., Suarez, N., Gurpide, A., Sangro, B., Hervas-Stubbs, S., Ochoa, C., Melero, J.A. and Melero, I. (2009) Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? Immunotherapy, 1, 845-853.
2. Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A. and Dudley, M.E. (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer, 8, 299-308.
3. Leen, A.M., Rooney, C.M. and Foster, A.E. (2007) Improving T cell therapy for cancer. Annu. Rev. Immunol., 25, 243-265.
4. Moosmann, A., Bigalke, I., Tischer, J., Schirrmann, L., Kasten, J., Tippmer, S., Leeping, M., Prevalsek, D., Jaeger, G., Ledderose, G. et al. (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood, 115, 2960-2970.
5. Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S.A., Yun, G.H., Fautsch, S.K., McKenna, D., Le, C., Defor, T.E., Burns, L.J. et al. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105, 3051-3057.
6. Brenner, M.K. and Heslop, H.E. (2010) Adoptive T cell therapy of cancer. Curr. Opin. Immunol., 22, 251-257.
7. Stewart, T.J. and Abrams, S.I. (2008) How tumours escape mass destruction. Oncogene, 27, 5894-5903.
8. Bollard, C.M., Rössig, C., Calonge, M.J., Huls, M.H., Wagner, H., Massague, J., Brenner, M.K., Heslop, H.E. and Rooney, C.M. (2002) Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood, 99, 3179-3187.
9. Westwood, J.A. and Kershaw, M.H. (2010) Genetic redirection of T cells for cancer therapy. J. Leukoc. Biol., 87, 791-803.
10. Di Stasi, A., De Angelis, B., Rooney, C.M., Zhang, L., Mahendravada, A., Foster, A.E., Heslop, H.E., Brenner, M.K., Dotti, G. and Savoldo, B. (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood, 113, 6392-6402.
11. De Angelis, B., Dotti, G., Quintarelli, C., Huye, L.E., Zhang, L., Zhang, M., Pane, F., Heslop, H.E., Brenner, M.K., Rooney, C.M. and Savoldo, B. (2009) Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood, 114, 4784-4791.
12. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P. et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314, 126-129.
13. Bonini, C., Brenner, M.K., Heslop, H.E. and Morgan, R.A. (2011) Genetic modification of T cells. Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant., 17, S15-S20.
14. Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L., Yang, J.C., Hughes, M.S., Kammula, U.S., Royal, R.E., Sherry, R.M., Wunderlich, J.R. et al. (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 114, 535-546.
15. Parkhurst, M.R., Yang, J.C., Langan, R.C., Dudley, M.E., Nathan, D.N., Feldman, S.A., Davis, J.L., Morgan, R.A., Merino, M.J., Sherry, R.M. et al. (2010) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther., doi:10.1038/mt.2010.272.
16. Bendle, G.M., Linnemann, C., Hooijkaas, A.I., Bies, L., de Witte, M.A., Jorritsma, A., Kaiser, A.D.M., Pouw, N., Debets, R., Kieback, E. et al. (2010) Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med., 16, 565-570 (1p following 570).
17. Rosenberg, S.A. (2010) Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol. Ther., 18, 1744-1745.
18. Moritz, D. and Groner, B. (1995) A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther., 2, 539-546.
19. Sadelain, M., Brentjens, R. and Rivière, I. (2009) The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol., 21, 215-223.
20. Beckman, R.A., Weiner, L.M. and Davis, H.M. (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer, 109, 170-179.
21. Weijtens, M.E., Willemsen, R.A., Valerio, D., Stam, K. and Bolhuis, R.L. (1996) Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J. Immunol., 157, 836-843.
22. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z. et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med., 14, 1264-1270.
23. Geiger, T.L., Nguyen, P., Leitenberg, D. and Flavell, R.A. (2001) Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood, 98, 2364-2371.
24. Pulè, M.A., Straathof, K.C., Dotti, G., Heslop, H.E., Rooney, C.M. and Brenner, M.K. (2005) A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther., 12, 933-941.
25. Brentjens, R.J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintás-Cardama, A., Larson, S.M. and Sadelain, M. (2007) Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res., 13, 5426-5435.
26. Ahmed, N., Salsman, V.S., Yvon, E., Louis, C.U., Perlaky, L., Wels, W.S., Dishop, M.K., Kleinerman, E.E., Pule, M., Rooney, C.M., Heslop, H.E. and Gottschalk, S. (2009) Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol. Ther., 17, 1779-1787.
27. Kohn, D.B., Dotti, G., Brentjens, R., Savoldo, B., Jensen, M., Cooper, L.J., June, C.H., Rosenberg, S., Sadelain, M. and Heslop, H.E. (2011) CARs on track in the clinic.Mol. Ther. J. Am. Soc. Gene Ther., 19, 432-438.
28. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.N., Lanier, B.J., Morgan, R.A. and Rosenberg, S.A. (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood, 116, 4099-4102.
29. Jena, B., Dotti, G. and Cooper, L.J.N. (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood, 116, 1035-1044.
30. Heslop, H.E. (2010) Safer CARS. Mol. Ther., 18, 661-662.
31. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M. and Rosenberg, S.A. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther., 18, 843-851.
32. Brentjens, R., Yeh, R., Bernal, Y., Riviere, I. and Sadelain, M. (2010) Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther., 18, 666-668.
33. Warren, E.H., Fujii, N., Akatsuka, Y., Chaney, C.N., Mito, J.K., Loeb, K.R., Gooley, T.A., Brown, M.L., Koo, K.K.W., Rosinski, K.V. et al. (2010) Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood, 115, 3869-3878.
34. Quintarelli, C., Vera, J.F., Savoldo, B., Giordano Attianese, G.M.P., Pule, M., Foster, A.E., Heslop, H.E., Rooney, C.M., Brenner, M.K. and Dotti, G. (2007) Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood, 110, 2793-2802.
35. Vera, J.F., Hoyos, V., Savoldo, B., Quintarelli, C., Giordano Attianese, G.M.P., Leen, A.M., Liu, H., Foster, A.E., Heslop, H.E., Rooney, C.M., Brenner, M.K. and Dotti, G. (2009) Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol. Ther., 17, 880-888.
36. Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H.E., Rooney, C.M., Brenner, M.K. and Dotti, G. (2010) Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia, 24, 1160-1170.
37. Markley, J.C. and Sadelain, M. (2010) IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood, 115, 3508-3519.
38. Heemskerk, B., Liu, K., Dudley, M.E., Johnson, L.A., Kaiser, A., Downey, S., Zheng, Z., Shelton, T.E., Matsuda, K., Robbins, P.F., Morgan, R.A. and Rosenberg, S.A. (2008) Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum. Gene Ther., 19, 496-510.
39. Craddock, J.A., Lu, A., Bear, A., Pule, M., Brenner, M.K., Rooney, C.M. and Foster, A.E. (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother., 33, 780-788.
40. Foster, A.E., Dotti, G., Lu, A., Khalil, M., Brenner, M.K., Heslop, H.E., Rooney, C.M. and Bollard, C.M. (2008) Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J. Immunother., 31, 500-505.
41. Terai, M., Tamura, Y., Alexeev, V., Ohtsuka, E., Berd, D., Mastrangelo, M.J. and Sato, T. (2009) Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol. Immunother., 58, 1307-1317.
42. Dotti, G., Savoldo, B., Pule, M., Straathof, K.C., Biagi, E., Yvon, E., Vigouroux, S., Brenner, M.K. and Rooney, C.M. (2005) Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood, 105, 4677-4684.
43. Heslop, H.E., Ng, C.Y., Li, C., Smith, C.A., Loftin, S.K., Krance, R.A., Brenner, M.K. and Rooney, C.M. (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med., 2, 551-555.
44. Heslop, H.E., Slobod, K.S., Pule, M.A., Hale, G.A., Rousseau, A., Smith, C.A., Bollard, C.M., Liu, H., Wu, M., Rochester, R.J. et al. (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 115, 925-935.
45. Plosker, G.L. and Foster, R.H. (2000) Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs, 59, 323-389.
46. Ciceri, F., Bonini, C., Stanghellini, M.T.L., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J. et al. (2009) Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol., 10, 489-500.
47. Tey, S., Dotti, G., Rooney, C.M., Heslop, H.E. and Brenner, M.K. (2007) Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant., 13, 913-924.
48. Smyth, M.J., Cretney, E., Kelly, J.M., Westwood, J.A., Street, S.E.A., Yagita, H., Takeda, K., van Dommelen, S.L.H., Degli-Esposti, M.A. and Hayakawa, Y. (2005) Activation of NK cell cytotoxicity. Mol. Immunol., 42, 501-510.
49. Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H. and Wels, W. (2002) Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood, 100, 1265-1273.
50. Müller, T., Uherek, C., Maki, G., Chow, K.U., Schimpf, A., Klingemann, H., Tonn, T. and Wels, W.S. (2008) Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol. Immunother., 57, 411-423.
51. Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pule, M. and Rossig, C. (2009) 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin. Cancer Res., 15, 4857-4866.
52. Zhang, J., Sun, R., Wei, H., Zhang, J. and Tian, Z. (2004) Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica, 89, 338-347.
53. Jiang, W., Zhang, J. and Tian, Z. (2008) Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL. Cytotherapy, 10, 265-274.
54. Goding, S.R., Yang, Q., Knudsen, K.B., Potter, D.M. and Basse, P.H. (2007) Cytokine gene therapy using adenovirally transduced, tumorseeking activated natural killer cells. Hum. Gene Ther., 18, 701-711.
55. Vera, J.F., Brenner, L.J., Gerdemann, U., Ngo, M.C., Sili, U., Liu, H., Wilson, J., Dotti, G., Heslop, H.E., Leen, A.M. and Rooney, C.M. (2010) Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J. Immunother., 33, 305-315.
56. Lee, D.A., Verneris, M.R. and Campana, D. (2010) Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol. Biol., 651, 61-77.
57. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., White, D.E., Wunderlich, J.R., Canevari, S., Rogers-Freezer, L. et al. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res., 12, 6106-6115.
58. Park, J.R., Digiusto, D.L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H.B., Bautista, C., Chang, W., Ostberg, J.R. and Jensen, M.C. (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther., 15, 825-833.
59. Lamers, C.H.J., Sleijfer, S., Vulto, A.G., Kruit, W.H.J., Kliffen, M., Debets, R., Gratama, J.W., Stoter, G. and Oosterwijk, E. (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol., 24, e20-e22.
60. Till, B.G., Jensen, M.C., Wang, J., Chen, E.Y., Wood, B.L., Greisman, H.A., Qian, X., James, S.E., Raubitschek, A., Forman, S.J. et al. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood, 112, 2261-2271.
61. Jensen, M.C., Popplewell, L., Cooper, L.J., DiGiusto, D., Kalos, M., Ostberg, J.R. and Forman, S.J. (2010) Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/ CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant., 16, 1245-1256.